Literature DB >> 3922377

Biliary excretion of FITC metabolites after administration of FITC labeled asialo orosomucoid as a measure of lysosomal proteolysis.

P van der Sluijs, R Oosting, J G Weitering, M J Hardonk, D K Meijer.   

Abstract

An isolated perfused rat liver system was used to study the hepatic uptake and degradation of asialo orosomucoid (asialo alpha 1-acid glycoprotein). To this aim we coupled the fluorochrome FITC to the asialoglycoprotein. The covalent attachment of FITC to the glycoprotein did not affect its perfusate disappearance. The disappearance rate was characterized by a t1/2 approximately equal to 6.1 min, the clearance being 11.2 ml/min. The internalized ligand was probably extensively degraded in the lysosomes as demonstrated by the appearance of low molecular weight fluorescent compounds in the bile, having a higher fluorescence yield than the native conjugate. Lysosomal degradation of ASOR-FITC was shown to be the rate limiting step in FITC excretion into the bile. Treatment of a perfused liver with varying doses of the protease inhibitor leupeptin did not influence the perfusate disappearance rate of the protein. However, leupeptin inhibited the biliary output of FITC metabolites in a dose dependent fashion, half maximal inhibition occurring at 210 nM (in the perfusion medium), corresponding with a dose of 0.05 mg leupeptin per 10 g liver. It is concluded that the rate of lysosomal degradation of proteins in vivo can be determined by measuring the biliary excretion of fluorescent material originating from fluorescent probes covalently coupled to the particular protein.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3922377     DOI: 10.1016/0006-2952(85)90676-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  2 in total

Review 1.  Covalent and noncovalent protein binding of drugs: implications for hepatic clearance, storage, and cell-specific drug delivery.

Authors:  D K Meijer; P van der Sluijs
Journal:  Pharm Res       Date:  1989-02       Impact factor: 4.200

2.  Alpha-1-acid (AAG, orosomucoid) glycoprotein: interaction with bacterial lipopolysaccharide and protection from sepsis.

Authors:  D F Moore; M R Rosenfeld; P M Gribbon; C P Winlove; C M Tsai
Journal:  Inflammation       Date:  1997-02       Impact factor: 4.092

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.